SHYMOL JOHN: Open Payments
NPI 1679115703 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,473 in 250 payments from 21 companies in 2025. Trend: 2023 $1,731 · 2024 $3,740 · 2025 $7,473
Food & beverage: $4,783Speaker / faculty: $2,640Education: $51
| Company | Payments | Amount |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 8 | $2,751 |
| ABBVIE INC. | 64 | $1,345 |
| Madrigal Pharmaceuticals | 22 | $717 |
| Janssen Biotech, Inc. | 38 | $529 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $297 |
| Ipsen Biopharmaceuticals, Inc | 14 | $223 |
| GENZYME CORPORATION | 12 | $202 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $192 |
| Regeneron Healthcare Solutions, Inc. | 7 | $183 |
| Lilly USA, LLC | 7 | $180 |
Products named: OCALIVA, REZDIFFRA, TREMFYA, RINVOQ, DUPIXENT, CREON, LINZESS, XIFAXAN.
Industry payments across OK — which companies pay providers there.
